(vianews) - vistin pharma (vistn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—specialty & generic industry.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vistin pharma (vistn.ol) | kr23.50 | 3.13% | 16.03% |
| ipsen (ipn.pa) | €105.10 | 1.08% | 12.52% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vistin pharma (vistn.ol)
3.13% forward dividend yield and 16.03% return on equity
vistin pharma asa, through its subsidiary, vistin pharma as, produces and sells active pharmaceutical ingredients (apis) worldwide. it offers metformin hcl apis and direct compressive granulates for the pharmaceutical industry. the company was founded in 1969 and is headquartered in oslo, norway.
earnings per share
as for profitability, vistin pharma has a trailing twelve months eps of kr1.
pe ratio
vistin pharma has a trailing twelve months price to earnings ratio of 23.5. meaning, the purchaser of the share is investing kr23.5 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.
earnings before interest, taxes, depreciation, and amortization
vistin pharma's ebitda is 30.28.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vistin pharma's stock is considered to be overbought (>=80).
yearly top and bottom value
vistin pharma's stock is valued at kr23.50 at 01:40 est, under its 52-week high of kr25.10 and way above its 52-week low of kr16.10.
more news about vistin pharma.
2. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. it offers somatuline for neuroendocrine tumors and acromegaly; dysport for motor muscular disorders and medical aesthetics; decapeptyl for the treatment of advanced metastatic prostate cancer; cabometyx for renal cell and second-line hepatocellular carcinoma; onivyde for second-line metastatic pancreatic cancer; and tazverik to treat third-line follicular lymphoma. the company also provides nutropinaq for growth failure in children due to growth hormone (gh) deficiency, turner syndrome or chronic renal insufficiency, and gh deficiency in adults; and increlex for growth failure in children and adolescents. in addition, it offers xermelo for the treatment of carcinoid syndrome; and cometriq to treat medullary thyroid cancer. ipsen s.a. has agreements with debiopharm; exelixis; galderma; blueprint medicines; tersera therapeutics; rhythm pharmaceuticals; teijin; schwabe; bakx therapeutics inc.; and exicure. the company was founded in 1929 and is headquartered in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €4.89.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 21.49. meaning, the purchaser of the share is investing €21.49 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
yearly top and bottom value
ipsen's stock is valued at €105.10 at 01:40 est, way below its 52-week high of €130.70 and way above its 52-week low of €94.85.
volatility
ipsen's last week, last month's, and last quarter's current intraday variation average was a positive 0.58%, a negative 0.04%, and a positive 1.22%.
ipsen's highest amplitude of average volatility was 0.58% (last week), 0.84% (last month), and 1.22% (last quarter).
more news about ipsen.